bemarituzumab + fluorouracil + leucovorin + oxaliplatin + docetaxel

A multi-agent combination regimen consisting of the **monoclonal antibody bemarituzumab** (targeting FGFR2b) together with **fluorouracil** (5-FU, a pyrimidine analog antimetabolite), **leucovorin** (folinic acid, a biomodulator enhancing fluorouracil), **oxaliplatin** (a platinum-based cytotoxic chemotherapy), and **docetaxel** (a taxane chemotherapeutic inhibiting microtubule depolymerization). - **Bemarituzumab** is a first-in-class, humanized IgG1 monoclonal antibody that selectively binds to and inhibits FGFR2b, blocking ligand-induced receptor activation and downstream signaling, with additional antibody-dependent cellular cytotoxicity (ADCC) activity[1][5]. - **Fluorouracil** is an antimetabolite that inhibits thymidylate synthase, blocking DNA synthesis. - **Leucovorin**, as folinic acid, stabilizes the binding of 5-FU to thymidylate synthase, enhancing its cytotoxic effect. - **Oxaliplatin** is a platinum-based agent causing DNA crosslinking and apoptosis. - **Docetaxel** is a taxane that disrupts microtubule dynamics, arresting cell division. This combination is under investigation as first-line therapy for **advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma** with **FGFR2b overexpression** (in ≥10% of tumor cells), particularly in patients who are HER2-negative. Clinical results (notably from the FORTITUDE-101 and FIGHT studies) demonstrate a significant improvement in progression-free and overall survival compared to chemotherapy alone, with a safety profile consistent with expectations for the component drugs[2][3][5][6][7][8].

Other names

bemarituzumab + FOLFOX6bemarituzumab + mFOLFOX6bemarituzumab plus chemotherapy